Targets › MAOB
3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 3; Neurology, Psychiatry; next expected readout Dec 2026.
Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. Preferentially…. (UniProt, P27338)
Open in Phaseline: the race on MAOB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Universita di Verona | Safinamide Monoamine oxidase B inhibitor | MAOB | Phase 3 | PARKINSON DISEASE (Disorder) | Dec 2027 |
| Guangzhou Henovcom Bioscience | HNC364 Injectable Suspension Rasagiline pro-drug; monoamine oxidase B (MAO-B) inhibitor | MAOB | Phase 1 | Parkinson's Disease (PD) | Dec 2026 |
| Corium Innovations | Selegiline Monoamine oxidase B inhibitor | MAOB | Phase 1 | Major Depressive Disorder (MDD) | – |
PARKINSON DISEASE (Disorder) (1) Parkinson's Disease (PD) (1) Major Depressive Disorder (MDD) (1)
small molecule (2), other (1)
Universita di Verona (1) Guangzhou Henovcom Bioscience (1) Corium Innovations (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.